Core Viewpoint - He Eye Hospital, a leading ophthalmology institution in Northeast China, is facing challenges including a significant reduction in shareholder value and management changes, alongside underperformance in multiple investment projects since its IPO in 2022 [1][2][4]. Group 1: Company Performance and Financials - He Eye Hospital's revenue is heavily concentrated in Liaoning Province, accounting for 94.31% of total revenue in 2024 [2]. - The company reported a net profit of 32.59 million yuan in 2022, a significant decline of 62.26% year-on-year, despite distributing dividends of 158 million yuan, which exceeded its net profit [2]. - For 2024, the company is projected to achieve a revenue of 1.096 billion yuan, reflecting a year-on-year decrease of 7.56%, with a net loss of 27.40 million yuan [3]. Group 2: Investment Projects and Challenges - Several investment projects initiated post-IPO have not met expected returns, with significant losses reported in projects such as the Beijing and Chongqing hospitals, which recorded losses of 90.85 million yuan and 69.51 million yuan respectively [4][5]. - The company has faced delays in project timelines, with the expected operational status for some projects pushed back to December 2026 and March 2027 [4][6]. Group 3: Management Changes and Shareholder Actions - In December 2025, the company underwent significant management changes, including the resignation of the general manager and the secretary of the board, which may impact operational stability [7][8]. - The fourth largest shareholder, Advanced Manufacturing Industry Investment Fund, has announced plans to reduce its stake by up to 310,610 shares, representing 1.97% of the total share capital, following a previous reduction in 2025 [8][9].
第四大股东拟再度减持背后：何氏眼科刚换总经理不久